Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose ranging study of topical Abafungin for interdigital tinea pedis
2005-002842-20Phase 2Completed
- Sponsor
- York Pharma
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abafungin in Athlete's foot (4 arms), sponsored by York Pharma. Primary endpoint: Treatment success rate at 6 weeks. Started Oct 2005; status: completed.
02
Drugs
abafungin
03
Conditions
Athlete's foot
Beyond the preview
Go deeper on 2005-002842-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002842-20.